Editors' Notes  by unknown
Cell Stem Cell
Editors’ NotesDebating Pluripotency
The online publication date of the paper from Rossi and colleagues showing that human iPSCs can be derived with
modified mRNAs and the escalation of the legal battle challenging U.S. federal funding of hESC research were close
in time purely by coincidence, but mainstream media coverage often discussed the two events together. Putting the
legal developments in context, this issue also includes a short Forum article from Gottweis, who outlines his view on
the background that led to the present U.S. situation and how a vocal population of abortion opponents have contrib-
uted to a glaring absence of comprehensive regulatory oversight of pluripotent cell research. Advances in iPSC tech-
nology are often hailed as strengthening the evidence that research on embryo-derived cells is not necessary. Arguing
against this view, however, is the growing body of evidence that we still have much to learn about
the origin, regulation, and potential of the many ‘‘flavors’’ of pluripotent cells, as discussed in
a Perspective from Buecker and Geijsen. The bulk of the research community still strongly favors
maintaining all lines of experimental inquiry using both embryo-derived and reprogrammed plurip-
otent cells. It remains to be seen whether international policy, and financial support, will also set
and uphold the same priorities.
Druggable Models?
Patient-derived iPSCsmay provide insight into disease progression or origin. For example, Ku and
colleagues generated iPSCs from Friedrich’s ataxia patients to study the mechanism of this DNA
repeat-based disease. They show that patient-derived iPSCs retain a repeat structure that resem-
bles the fibroblast cell of origin and, strikingly, that iPSC generation seems to mimic the repeat
instability seen when mutant genes pass between generations. They also implicate the mismatch
repair enzyme MSH2 as a participant in the repeat instability. Whether these basic studies might
open the door to the identi help identify specific drug candidates remains unclear, but the mouse
studies conducted by Cao and coauthorsmight have relatively short term clinical implications. Using a TGF-b-deficient
animal model, the authors demonstrate that active TGF-b is required to attract skeletal stem cells to sites of active bone
resorption and speculate that thismechanism underlies the observation that sequential dosing of patients with anabolic
drugs, like PTH, and anti-resorptive compounds, like alendronate, is more effective than concurrent exposure during
the treatment of osteoporosis. Steven Teitelbaum discusses the clinical context and implications of these findings in
a short In Translation article.
Communicating Fate
Belmonte and colleagues provide their Perspective on the importance of epigenetic control over developmental
progression and how the flexibility of cell fate options exhibited by stem and progenitor cells can be modified by the
environment, be manipulated during reprogramming, or perhaps menace an organism by raising
an oncogenic risk. The role of chromatin remodelers in regulating environmentally induced cell fate
decisions is also featured in the Research Article from Drummond-Barbosa and coauthors, who
used a sex-steroid paralog in a Drosophila model to demonstrate that insulin-independent
hormone regulation of germ stem cell self-renewal can function at the level of the ISWI-containing
NURF remodelling complex. This work, therefore, connects systemic modulation of the stem cell
niche down to the epigenetic level of cell fate regulation.
The Good and the Bad
The expansion capacity of hematopoietic progenitors carries a risk of DNA damage or mutation
and subsequent oncogenic transformation, which necessitates a strong level of apoptotic
control. Lozano and colleagues identify the E3 ubiquitin ligase Mdm2 as an important player
in this pathway and demonstrate that it is required to keep p53-mediated ROS in check and
to prevent accumulation of p16 during hematopoiesis. The impact of the p53 pathway on
primitive blood cells was also under scrutiny by Morrison and colleagues in the context of
mTor-mediated depletion of normal HSCs. These authors have previously used rapamycin to inhibit mTor and block
the expansion of leukemia-initiating cells in Pten deficient mice, whereas the same treatment rescues nonleukemic
HSCs in that genetic background. In this study, they uncover more mechanistic insight, showing that the p53 tumor
suppressor pathway is turned on in HSCs after mTor activation, and leukemogenic clones appear to bypass this
quality control step by accumulating secondary mutations. Identification of pathways responsible for the cell-
specific response to rapamycin represents an important step toward tailoring clinical therapies to individual tumor
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